Panbela Therapeutics logo
  • About Us
    • Company Overview
    • Management
    • Board of Directors
    • Scientific Advisory Board
  • Our Science
    • Overview of SBP-101
    • Science
    • Pipeline
    • Clinical Trials
    • Expanded Access Policy
  • Newsroom
    • Press Releases
    • Events & Presentations
  • Investor Relations
    • Corporate Governance
    • Financial Information
    • Annual Reports & Proxy Statements
    • Investor Contact Info
  • Contact

Annual Reports & Proxy Statements

  • Overview
  • Corporate Governance
  • Financial Information
  • Annual Reports & Proxy Statements
  • Investor Contact Information

Sun BioPharma 2019 Annual Report including 2020 Proxy Statement »
Sun BioPharma 2018 Annual Report including 2019 Proxy Statement »
Sun BioPharma 2017 Annual Report including 2018 Proxy Statement »
Sun BioPharma Notice of Consent Solicitation »
Sun BioPharma 2016 Annual Report including 2017 Proxy Statement »
Sun BioPharma 2015 Annual Report including 2016 Proxy Statement »

Quick Links

  • Home
  • About Us
  • Our Science
  • Newsroom
  • Investor Relations
  • Contact

Contact

bd@panbela.com
 
Sign up to receive press releases via email:

News & Events

  • PBLA Completes Enrollment in Phase 1b Trial Investigating SBP-101 Combination Therapy for First Line Metastatic Pancreatic Cancer
  • Sun BioPharma, Inc. Changes Name to Panbela Therapeutics Inc.
  • SBP Provides Business Update and Reports Q3 2020 Financial Results
Copyright ©2021 Panbela Therapeutics, Inc. All Rights Reserved.